Table 1. Phase III clinical trials of novel combination regimens for first‐line therapy for metastatic renal cell carcinoma.
Primary completion date: The date on which the last participant in the clinical study was examined or received an intervention to collect final data for the primary outcome measure.
Abbreviations: OS, overall survival; PFS, progression‐free survival.